In a cohort of 51 advanced BC patients, flow cytometry data from PB revealed an increase in activated OX40+/PD-1− T lymphocytes and a decrease in inhibitory myeloid cells and Tregs, which correlated with the clinical benefit upon systemic treatment [106]. This evidence concerns the gene TNFRSF4 and breast cancer.